Personalized Secukinumab Treatment for Psoriasis
Author Information
Author(s): Rodriguez-Fernandez Karine, Zarzoso-Foj Javier, Saez-Bello Marina, Mateu-Puchades Almudena, Martorell-Calatayud Antonio, Merino-Sanjuan Matilde, Gras-Colomer Elena, Climente-Marti Monica, Mangas-Sanjuan Victor
Primary Institution: University of Valencia
Hypothesis
Can model-informed precision dosing improve treatment outcomes for patients with plaque psoriasis?
Conclusion
The study suggests that personalized dosing regimens for secukinumab can optimize treatment for psoriasis patients, with many requiring adjustments to their current therapy.
Supporting Evidence
- 50% of patients required an optimized regimen.
- 14% of patients needed an intensified dosage regimen.
- The study used a population pharmacokinetic/pharmacodynamic model to tailor treatments.
Takeaway
This study shows that doctors can use special models to give the right amount of medicine to people with psoriasis, helping them get better faster.
Methodology
A prospective, observational study was conducted to evaluate personalized dosing regimens of secukinumab in patients with moderate to severe plaque psoriasis.
Potential Biases
Potential biases may arise from the observational nature of the study and the reliance on clinical records.
Limitations
The study had a small sample size and some missing data points, which may affect the results.
Participant Demographics
{"mean_age":50.07,"gender_distribution":{"male":14,"female":8},"body_weight":{"mean":74.5,"range":"46-97"}}
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website